FOLH1 and cancer: Radiopharmaceutical therapy (RPT) is becoming a critical pillar in cancer treatment, exemplified by U.S. Food and Drug Administration approvals of [177Lu]Lu-PSMA-617 (1) and [177Lu]Lu-DOTATATE (2) for managing advanced-stage prostate and neuroendocrine tumors.